Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
November 01, 2023 16:00 ET
|
Gynesonics
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids Reaches Patient Milestones in the U.S. and Globally
October 25, 2023 16:07 ET
|
Gynesonics
Gynesonics is pleased to announce that its Sonata Procedure has been used to treat over 1,000 women in the United States in 2023
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids Reaches Patient Milestones in the U.S. and Globally
October 17, 2023 12:00 ET
|
Gynesonics
Gynesonics' Sonata® Procedure has been used to treat over 1,000 women in the United States and approximately 6,500 women globally.
Gynesonics Names Industry Veteran Skip Baldino President and CEO, Announces $25M Financing to Expand Worldwide Commercialization
April 11, 2023 12:00 ET
|
Gynesonics
REDWOOD CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids,...
The Fibroid Foundation Announces Fibroid Awareness Month 2022
July 06, 2022 15:30 ET
|
The Fibroid Foundation
WASHINGTON, July 06, 2022 (GLOBE NEWSWIRE) -- The Fibroid Foundation announces the Fibroid Awareness Month event schedule for July 2022. This Year's Fibroid Awareness Month Theme is 'Real...
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
June 28, 2022 16:01 ET
|
ObsEva SA
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
June 17, 2022 07:00 ET
|
ObsEva SA
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
June 17, 2022 01:00 ET
|
ObsEva SA
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
May 25, 2022 07:00 ET
|
ObsEva SA
-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
May 25, 2022 01:00 ET
|
ObsEva SA
-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th...